Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval
Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Runimotamab by Genentech USA for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Runimotamab is under clinical development by Genentech USA and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
Runimotamab by Genentech USA for Gastric Cancer: Likelihood of Approval
Runimotamab is under clinical development by Genentech USA and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...